The first element, 96%, can be interpreted as a representation of the nearly universal agreement on the need for change. In global conversations, especially regarding climate change, innovation, and social justice, studies reveal that a significant majority—around 96%—recognize the urgency of the issues at hand. This consensus demonstrates that individuals, organizations, and governments are increasingly aware of their environmental and social responsibilities. With almost everyone on the same page, the challenge lies in translating this awareness into concrete action.
In the era of smart manufacturing, the development of pharma intermediates is also experiencing new opportunities. Utilizing advanced technologies like big data, artificial intelligence, and continuous flow chemistry, pharmaceutical companies can precisely control synthesis reactions, achieving efficient production of intermediates and customized batches of antibiotics. For example, real-time monitoring of reaction conditions and automatic parameter adjustments can significantly increase the yield and purity of intermediates, reduce by-product formation, and optimize antibiotic production processes.